Bristol Myers Squibb is paying $50 million to begin a collaboration with Janux Therapeutics, a company that develops T cell engagers that activate specifically at the site of the tumor. It’s the second big pharma alliance for Janux, which has been working with Merck.
The post BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy appeared first on MedCity News.
